Cardiff Oncology, Inc. — FY2022 Form 10-K
Business context and reporting period. Cardiff Oncology is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor, in combination with standard-of-care therapies. The fiscal year ended December 31, 2022; the filing reports annual results, not separate Q4 financial results. Its programs include metastatic colorectal and pancreatic cancers, triple-negative breast cancer, and small-cell lung cancer. The company had no approved product and generated only limited royalty revenue from legacy intellectual-property licenses.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $0.386 million | $0.359 million |
| Research and development expense | $27.107 million | $17.376 million |
| Selling, general and administrative expense | $13.181 million | $11.838 million |
| Net loss attributable to common stockholders | $38.728 million | $28.315 million |
| Basic and diluted loss per share | $0.89 | $0.73 |
| Net cash used in operating activities | $33.820 million | $23.040 million |
- Revenue consists of royalties on licenses unrelated to onvansertib. Product gross margin is not meaningful for this pre-commercial business.
- At year-end, cash and cash equivalents were $16.347 million and short-term investments were $88.920 million, totaling $105.267 million. Working capital was $103.5 million, down from $139.6 million.
- Management said these resources were sufficient for at least 12 months from issuance of the financial statements and, based on current projections, expected to fund operations into 2025. It also expects continued losses and operating cash outflows and anticipates needing additional capital.
- No borrowings are reported on the balance sheet. Operating lease liabilities totaled $2.715 million, including $0.675 million current. Total liabilities were $9.848 million.
- Net cash provided by investing activities was $38.149 million, mainly reflecting investment maturities and sales exceeding purchases; financing activities provided $0.075 million. The company reported $4.256 million of stock-based compensation.
Material changes versus FY2021
- Net loss attributable to common stockholders increased $10.413 million, principally as operating expenses rose. R&D expense increased $9.731 million, driven mainly by clinical, CMC, clinical-pharmacology, and other onvansertib development costs.
- Operating cash use increased $10.780 million. The company received $35.450 million from financing activities in FY2021, compared with $0.075 million in FY2022.
- Cash and short-term investments fell from $140.821 million to $105.267 million; working capital declined by $36.1 million.
- Weighted-average common shares outstanding increased to 43.6 million from 39.0 million. During 2022, 2.684 million common shares were issued on conversion of Series E preferred stock; no Series E preferred shares remained outstanding at year-end.
Clinical outlook, risks, and unusual items
- Colorectal cancer: TROV-054 completed enrollment in October 2022. In the company-reported update, 17 of 48 evaluable patients responded (ORR 35%); median duration of response was 11.7 months and median progression-free survival was 9.3 months. This was a single-arm trial; comparisons with historical controls are not randomized evidence. The bevacizumab-naive subgroup had ORR of 69% and median PFS of 13.5 months (n=13), versus 23% and 7.8 months among previously treated patients (n=35). ONSEMBLE, a randomized Phase 2 trial planned for approximately 150 patients, opened in Q4 2022; topline data were anticipated in 2H 2024.
- Other trials: Preliminary pancreatic-cancer data reported one partial response and three cases of stable disease among five evaluable patients; additional data were anticipated in mid-2023. Preliminary TNBC data were anticipated in Q4 2023 or Q1 2024, and SCLC data in mid-2023. These are management expectations, not guaranteed timelines or outcomes.
- Funding and development risks: The company has a $298.1 million accumulated deficit and relies on external financing. Clinical outcomes, regulatory review, trial enrollment, manufacturing and third-party vendor performance are uncertain; future equity financing could dilute shareholders. Onvansertib is licensed from Nerviano, and loss of that license could materially harm the program.
- Unusual accounting/tax matters: A fourth-quarter 2022 correction removed a $0.4 million accrued liability for Series A cumulative dividends not declared by the board; the filing characterizes the error as immaterial. A Section 382/383 review identified ownership changes that reduced prior-period federal and state NOL carryforwards by approximately $123.9 million and $62.8 million, respectively, and reduced federal tax credits by approximately $1.8 million. A full valuation allowance remains against deferred tax assets.
- The company reported no claims believed likely to have a material adverse effect. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not express an opinion on internal-control effectiveness.
Important facts for investors to verify
- Confirm the composition, liquidity, maturity profile, and subsequent movement of the $105.3 million cash-and-investment balance, and compare actual spending with management’s runway assumptions.
- Track randomized ONSEMBLE results, trial enrollment and timing, and whether the TROV-054 single-arm results are replicated in controlled studies.
- Assess the assumptions and estimates behind trial accruals: the year-end clinical-trial accrual was $2.3 million and was identified as a critical audit matter.
- Review future financing needs, potential dilution, and any changes to the stated expectation of funding operations into 2025.
- Verify the impact of NOL limitations, the terms and obligations of the Nerviano license, and any changes in material clinical, regulatory, manufacturing, or legal risks.